A large proportion of breast cancers express receptors for estrogen/progesterone (hormone receptor-positive, HR+) while lacking the over-expression of HER2 (HER2−) (corresponding mainly to the luminal A PAM50 categorization). Here, ERBB2 is linked to breast cancer.